Novo Nordisk settles US patent litigation case on Victoza liraglutide with Teva

Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva

02:53 EDT 20 Mar 2019 | Pharmaceutical Business Review

Consequently, Teva is licensed to launch a generic version of Victoza as of 22 December 2023. Under certain circumstances Teva could launch a generic version of Victoza earlier,

The post Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva appeared first on Pharmaceutical Business review.

More From BioPortfolio on "Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva"